Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 21

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 21
---
 that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for us. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of cybersecurity risk management as well as incidental reports as matters arise. Our Nominating and Corporate Governance Committee monitors the effectiveness of our Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as possible. The Board has delegated to the Board’s chair the responsibility of coordinating between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues.

<div align='center'>13</div>

#### MEETINGS OF THE BOARDOur Board met four times during the fiscal year ended December 31, 2024. During the fiscal year ended December 31, 2024, each director attended 100% of the four meetings of our Board and each of the committee meetings on which he or she served as a director or committee member. We encourage our directors and nominees for director to attend our Annual Meeting of Stockholders, but have no policy requiring them to do so.INFORMATION REGARDING COMMITTEES OF THE BOARDOur Board has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for the fiscal year ended 2024 for each of the Board committees:​​​​​​​​​Nominating and​​​​​​CorporateName​Audit​Compensation​GovernanceGene MackKhalid Islam, Ph.D.Dov Goldstein, M.D.X*​XHans Peter HaslerX​X*Gwen Melincoff​XClaude Nicaise, M.D.​XXEric I. RichmanJeffrey RileyXX*Total meetings in fiscal year 2024444*Committee ChairpersonOur Board has determined that each member of each standing committee meets the applicable Nasdaq rules and regulations regarding “independence,” and each member